News
RNAZ
0.5121
+16.41%
0.0722
Weekly Report: what happened at RNAZ last week (0415-0419)?
Weekly Report · 3d ago
TransCode Therapeutics: A Promising Oncology Investment with FDA-Backed Clinical Advancements
TipRanks · 04/15 16:35
TRANSCODE THERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE PHASE 1/2 CLINICAL TRIAL WITH TTX-MC138 IN PATIENTS WITH ADVANCED SOLID TUMORS
Reuters · 04/15 13:00
Weekly Report: what happened at RNAZ last week (0408-0412)?
Weekly Report · 04/15 11:26
Weekly Report: what happened at RNAZ last week (0401-0405)?
Weekly Report · 04/08 11:30
Transcode Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones · 04/03 16:14
Promising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode Therapeutics
TipRanks · 04/03 16:05
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
Benzinga · 04/03 16:03
TransCode Therapeutics reports FY results
TransCode Therapeutics, Inc. Reports FY results. FY operating loss was $19.4 million compared to $18.6 million in 2022. Research and development expenses were $12.3 million in 2023. Cash was $2.8 million on December 31, 2024.
Seeking Alpha · 04/03 14:29
TRANSCODE THERAPEUTICS REPORTS 2023 RESULTS; PROVIDES BUSINESS UPDATE
Reuters · 04/03 13:10
Press Release: TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics reports 2023 Results; Provides Business Update. Company's lead therapeutic candidate, TTX-MC138, is approved for FDA-cleared first-in-human Phase 0 clinical trial against metastatic cancer. The company raised over $25 million in equity financings in 2023.
Dow Jones · 04/03 13:10
Weekly Report: what happened at RNAZ last week (0325-0329)?
Weekly Report · 04/01 11:28
TransCode Therapeutics appoints Vlock as chief medical officer
TransCode Therapeutics appoints Daniel Vlock as chief medical officer. Vlock is a medical oncologist with over 25 years of industry experience The company is a subsidiary of TransCode Pharmaceuticals, Inc. (NASDAQ:RNAZ)
Seeking Alpha · 03/28 13:01
Press Release: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer. Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy. Dr. Vlock is a leading expert in the field of oncology. TransCode is committed to more effectively treating cancer using RNA therapeutics.
Dow Jones · 03/28 12:30
Weekly Report: what happened at RNAZ last week (0318-0322)?
Weekly Report · 03/25 11:31
Weekly Report: what happened at RNAZ last week (0311-0315)?
Weekly Report · 03/18 11:29
Weekly Report: what happened at RNAZ last week (0304-0308)?
Weekly Report · 03/11 11:26
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
TransCode Therapeutics, Inc. Will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland. The conference is focused on the development of mRNA, RNAi and other RNA targets. TransCode is committed to more effectively treating cancer using RNA therapeutics.
Barchart · 03/06 15:15
Weekly Report: what happened at RNAZ last week (0226-0301)?
Weekly Report · 03/04 11:29
Weekly Report: what happened at RNAZ last week (0219-0223)?
Weekly Report · 02/26 11:43
More
Webull provides a variety of real-time RNAZ stock news. You can receive the latest news about Transcode Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.